Answers are grounded in this paper and cite their sources.
This proposal demonstrates a novel strategy to reactivate fetal hemoglobin for malaria prevention, suggesting an innovative approach to treatment.
This paper proposes a novel, durable strategy for malaria prevention by reactivating Fetal Hemoglobin (HbF) through targeted epigenomic editing of the BCL11A erythroid-specific enhancer. Unlike traditional CRISPR-Cas9 approaches that induce permanent DNA breaks, our strategy utilizes a dCas9-DNMT3A-DNMT3L fusion protein to induce site-specific CpG methylation, effectively silencing the BCL11A repressor in Hematopoietic Stem Cells (HSCs).
No takes yet. Share an insight, caveat, or question.
do gyeom Kim (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: